New participant in digital diabetes administration 

Diabetes app Smit.match from India and Qatar-based digital therapeutics (DTx) firm Droobi Well being have introduced their merger. 

The mixed entity referred to as DroobiSmit, headquartered in Singapore, goals to be a number one diabetes answer supplier within the Center East and South Asia areas. It would supply personalised options for individuals with pre-diabetes, diabetes, and hypertension, leveraging digital twin know-how, predictive analytics, and superior monitoring. 

Sujit Chakrabarty, founding father of Smit.match who may also be on the helm of DroobiSmit, talked about that they’ll look to enter rising markets, significantly Saudi Arabia. Former Qatari Minister of Telecommunications Dr Hessa Al Jaber can also be set to affix the corporate’s board. 

Fitterfly launches empathetic AI chatbot 

Fitterfly, a DTx firm from India, has harnessed AI applied sciences to develop an empathetic conversational chatbot that assists with well being and health administration. 

Dubbed JEDi, this chatbot on the Fitterfly Metabolic Well being app provides customised recommendation and nudges primarily based on consumer responses, well being knowledge, and preferences.

“The JEDi structure is hybrid with rule-based [natural language processing] on an Skilled system basis complemented with massive language fashions. It is linked to the Fitterfly data base which powers our therapies,” Ammar Jagirdar, head of X Labs at Fitterfly, mentioned, explaining the chatbot structure.

JEDi can even come as a plug-and-play answer or an add-on service for corporates, together with insurance coverage corporations.

Nuvilab’s new cell answer options genAI, CGM tech

South Korean meals AI firm Nuvilab has provide you with a brand new cell answer for managing the vitamin of individuals with diabetes.

With out giving out many particulars on the brand new answer, the corporate shared that it’s incorporating steady glucose monitoring (CGM) and generative AI to boost its effectiveness. 

The launch of this new providing comes as Nuvilab is increasing its healthcare service targets to incorporate individuals with Kind 2 diabetes. 

In the meantime, the corporate lately signed a proper contract to implement its AI meals scanner within the inpatient care of Alexandra Hospital in Singapore, following a profitable seven-week pilot. The scanner has a 95% common accuracy in recording and analysing meals of sufferers per mattress. 

Qure.ai’s newest FDA approval for AI CXR answer 

Indian medical imaging options supplier Qure.ai has bagged one other clearance from the US Meals and Drug Administration for its AI-based chest X-ray answer. 

qXR for Lung Nodule is reportedly the primary FDA-approved answer for figuring out and localising lung nodules utilizing laptop imaginative and prescient, supposed to be used by radiologists, pulmonologists, and ER physicians. The answer can detect and spotlight areas with suspected pulmonary nodules which can be 6-30 millimetres in dimension. 

It’s the firm’s thirteenth FDA clearance and the sixth for its vary of chest X-ray options.

Oncoshot to energy scientific trials at Ablaze with superior analytics 

Singaporean medical AI startup Oncoshot has partnered with scientific trial options supplier Zhejiang Ablaze Medication from China to optimise scientific trial infrastructure. 

Oncoshot will embed superior analytics and automation to raise Ablaze’s trial design and planning. It would additionally ship federated knowledge infrastructure to assist Ablaze and its companions. 

Their purpose, in keeping with Ablaze co-founder and director Marco Meng, is to “assist predict optimum trial websites, improve affected person matching and retention, and allow a steady cycle of trial design enhancements powered by knowledge and know-how.”